These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 38603534)

  • 1. Adjusting starting points for initial price offers: the example of ibrutinib.
    Gibbons JB; Bennett CL; Carson KR; Anderson GF
    Am J Manag Care; 2024 Apr; 30(4):193-196. PubMed ID: 38603534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Price benchmarks of drugs selected for Medicare price negotiation and their therapeutic alternatives.
    Hernandez I; Cousin EM; Wouters OJ; Gabriel N; Cameron T; Sullivan SD
    J Manag Care Spec Pharm; 2024 Aug; 30(8):762-772. PubMed ID: 38905356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medicare Drug Price Negotiation in the United States: Implications and Unanswered Questions.
    Sullivan SD
    Value Health; 2023 Mar; 26(3):394-399. PubMed ID: 36503034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Examining Opportunities to Increase Savings From Medicare Price Negotiations.
    Reitsma MB; Dusetzina SB; Ballreich JM; Trujillo AJ; Mello MM
    JAMA Intern Med; 2023 Jun; 183(6):581-588. PubMed ID: 37067794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Inflation Reduction Act: How Will Medicare Negotiating Drug Prices Impact Patients with Heart Disease?
    Johnson M; Kishore S; Nayak RK; Dusetzina SB
    Curr Cardiol Rep; 2023 Jun; 25(6):577-581. PubMed ID: 37097432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simulated Medicare Drug Price Negotiation Under the Inflation Reduction Act of 2022.
    Rome BN; Nagar S; Egilman AC; Wang J; Feldman WB; Kesselheim AS
    JAMA Health Forum; 2023 Jan; 4(1):e225218. PubMed ID: 36705916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medicare Part B and Part D drug eligibility for center for Medicare and Medicaid Services price negotiation under the Inflation Reduction Act: estimates using 2016-2019 data.
    Qureshi O; Ramachandran R; Ross JS
    J Pharm Policy Pract; 2024; 17(1):2312374. PubMed ID: 38434725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrating Price Benchmarks and Comparative Clinical Effectiveness to Inform the Medicare Drug Price Negotiation Program.
    Sullivan SD; Wouters OJ; Cousin EM; Kirihennedige AS; Hernandez I
    Value Health; 2024 Oct; 27(10):1348-1357. PubMed ID: 39154910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medicare price negotiation and pharmaceutical innovation following the Inflation Reduction Act.
    Vogel M; Kakani P; Chandra A; Conti RM
    Nat Biotechnol; 2024 Mar; 42(3):406-412. PubMed ID: 38297186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Access in all areas? A round up of developments in market access and health technology assessment: part 2.
    Beattie A; Treharne C; Mardiguian S; Ramagopalan SV
    J Comp Eff Res; 2023 Dec; 12(12):e230162. PubMed ID: 37916681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Constitutionality of Medicare Drug-Price Negotiation under the Takings Clause.
    Bhargava R; Brown N; Kapczynski A; Kesselheim AS; Lim SY; Morten CJ
    J Law Med Ethics; 2023; 51(4):961-971. PubMed ID: 38477274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association Between Market Competition and Prices of Generic Topical Dermatology Drugs.
    Li DG; Joyce C; Mostaghimi A
    JAMA Dermatol; 2018 Dec; 154(12):1441-1446. PubMed ID: 30383117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimated discounts generated by Medicare drug negotiation in 2026.
    Hernandez I; Gabriel N; Dickson S
    J Manag Care Spec Pharm; 2023 Aug; 29(8):868-872. PubMed ID: 37523318
    [No Abstract]   [Full Text] [Related]  

  • 14. Estimated Savings From Using Added Therapeutic Benefit and Therapeutic Reference Pricing in United States Medicare Drug Price Negotiations.
    DiStefano MJ; Levy JF; Odouard IC; Anderson GF
    Value Health; 2023 Nov; 26(11):1618-1624. PubMed ID: 37689264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association Between the Percentage of US Drug Sales Subject to Inflation Penalties and the Extent of Drug Price Increases.
    Dickson S
    JAMA Netw Open; 2020 Sep; 3(9):e2016388. PubMed ID: 32915237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Inflation Reduction Act: A boon for the generic and biosimilar industry.
    Niazi SK
    J Clin Pharm Ther; 2022 Nov; 47(11):1738-1751. PubMed ID: 36207987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medicare drug price negotiation: The complexities of selecting therapeutic alternatives for estimating comparative effectiveness.
    Hernandez I; Cousin EM; Wouters OJ; Gabriel N; Cameron T; Sullivan SD
    J Manag Care Spec Pharm; 2024 Mar; 30(3):218-225. PubMed ID: 38088899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends in Pricing and Generic Competition Within the Oral Antibiotic Drug Market in the United States.
    Alpern JD; Zhang L; Stauffer WM; Kesselheim AS
    Clin Infect Dis; 2017 Nov; 65(11):1848-1852. PubMed ID: 29020146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Inflation Reduction Act: An Opportunity to Accelerate Confidence in Real-World Evidence in the United States.
    Arora P; Gupta A; Mackay E; Heeg B; Thorlund K
    Value Health; 2024 Aug; 27(8):999-1002. PubMed ID: 38636697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using a patient-centered value assessment to optimize fair prices for Inflation Reduction Act's Medicare Drug Price Negotiation Program.
    Poudel N; Ngorsuraches S
    J Manag Care Spec Pharm; 2024 Mar; 30(3):241-246. PubMed ID: 38140902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.